The FDA has revoked Inovio's investigational new drug (IND) application until the company answers additional questions about the planned phase II/III trial to investigate INO-4800 and the associated Cellectra 2000 delivery device.

Inovio said it is working to address the administration's questions and plans to respond in October. Once the answers are received, the FDA has up to 30 days to notify Inovio whether the trial can proceed as planned.

The IND revocation does not affect Inovio's ongoing phase I study of INO-4800 or other vaccine candidates in development. It was also not issued because of the occurrence of any adverse event related to the vaccine candidate, Inovio noted.

Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.

Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations...

Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...

Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...